Table 1 Baseline characteristics of randomised patients
From: Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis
Characteristic | Sitagliptin | Non-exposed |
|---|---|---|
| Â | (n = 7,726) | (n = 6,885) |
Age, years | 54.0 ± 10.3 | 54.4 ± 10.5 |
Age ≥65 years, n (%) | 1,261 (16) | 1,185 (17) |
Gender, n (%) | Â | Â |
 Male | 4,196 (54) | 3,788 (55) |
 Female | 3,530 (46) | 3,097 (45) |
Race, n (%) | Â | Â |
 Caucasian | 4,674 (60) | 4,227 (61) |
 Black | 427 (6) | 384 (6) |
 Asian | 1,436 (19) | 1,227 (18) |
 Multiracial | 462 (6) | 427 (6) |
 Other or unknown | 727 (9) | 620 (9) |
Ethnicity, Hispanic or Latino, n (%) | 1,917 (25) | 1,690 (25) |
Body weight, kg | 85.0 ± 19.6 | 85.8 ± 20.1 |
Body mass index, kg/m2 | 30.5 ± 5.7 | 30.7 ± 5.8 |
Duration of T2DM, years* | 3.0 | 4.0 |
Distribution of duration of T2DM, n (%)†|  |  |
<5 years | 4,535 (59) | 4,002 (58) |
≥5 and <10 years | 1,864 (24) | 1,690 (25) |
≥10 years | 1,316 (17) | 1,188 (17) |
HbA1c, % | 8.4 ± 1.3 | 8.4 ± 1.3 |
HbA1c distribution at baseline, n (%) | Â | Â |
 HbA1c <8% | 3,190 (41) | 2,924 (42) |
 HbA1c ≥8 to <9% | 2,258 (29) | 1,931 (28) |
 HbA1c ≥9% | 2,264 (29) | 2,016 (29) |
History of CVD, n (%) | 792 (10) | 691 (10) |
Proportion of patients with known CV risk factors other than T2DM and history of CVD, n (%)††| 5,827 (81) | 5,266 (82) |
 History of dyslipidaemia, n (%) | 3,857 (50) | 3,350 (49) |
 History of hypertension, n (%) | 4,110 (53) | 3,666 (53) |
 History of smoking, n (%)††| 2,712 (38) | 2,539 (39) |